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Abstract
Our understanding of the molecular mechanisms of many neurological disorders has been greatly enhanced by the
discovery of mutations in genes linked to familial forms of these diseases. These have facilitated the generation of cell and
animal models that can be used to understand the underlying molecular pathology. Recently, there has been a surge of
interest in the use of patient-derived cells, due to the development of induced pluripotent stem cells and their subsequent
differentiation into neurons and glia. Access to patient cell lines carrying the relevant mutations is a limiting factor for many
centres wishing to pursue this research. We have therefore generated an open-access collection of fibroblast lines from
patients carrying mutations linked to neurological disease. These cell lines have been deposited in the National Institute for
Neurological Disorders and Stroke (NINDS) Repository at the Coriell Institute for Medical Research and can be requested by
any research group for use in in vitro disease modelling. There are currently 71 mutation-defined cell lines available for
request from a wide range of neurological disorders and this collection will be continually expanded. This represents a
significant resource that will advance the use of patient cells as disease models by the scientific community.
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Introduction
Neurodegenerative diseases, including Alzheimer’s disease (AD),
Parkinson’s disease (PD), frontotemporal dementia, amyotrophic
lateral sclerosis (ALS), Huntington’s disease (HD), ataxias and
dystonias are a major socioeconomic problem, and understanding
the biological basis of neuronal death in these disorders is a major
challenge for basic research. Many of the loci responsible for early-
onset, familial forms of these disorders have been identified.
Mutations in APP, PS1 and PS2 are associated with AD [1–4],
SNCA, LRRK2, PRKN, PINK1 and GBA [5–9] are associated with
PD; SOD1, TARDP and FUS mutations lead to familial ALS [10–
12]; frontotemporal dementia and parkinsonism linked to chro-
mosome-17 is associated with MAPT (FTDP-17T) and PGRN
mutations (FTDP-17U/GRN) [13–15]; and CAG expansion of
the HTT gene causes HD [16].
Using this genetic information as a basis for developing cell and
animal models has greatly enhanced our understanding of the
biological mechanisms underlying neuronal degeneration in these
disorders. However, current cell models of neurological disease are
limited by two major drawbacks: non-physiological protein
expression levels and/or a non-neuronal cell type [17–19].
Patient-derived cells such as fibroblasts have been used as models
in several studies looking at the basis of neurological disorders,
including AD [20]. Recently, human somatic cells, such as
fibroblasts, were reprogrammed to pluripotency by the exogenous
expression of the transcription factors OCT4, SOX2, KLF4
NANOG, LIN28 and MYC [20–22]. These induced pluripotent
stem cells (iPSC) can be subsequently differentiated into neurons
and glia, therefore by generating iPSC from patients carrying
disease-linked mutations physiological expression of mutated genes
in the cell type specifically affected in disease can be achieved. This
technology has already been used to successfully model a range of
neurological diseases including AD, PD, ALS and Ataxia [23–27].
Despite the fact that many of these diseases are adult onset,
several groups have used iPSCs to model aspects of disease
pathology. Perhaps the most notable of these is AD, where cells
derived from patients with mutations in several genes have
successfully recapitulated common pathology. Neurons generated
from patients carrying point mutations in PSEN1, APP duplica-
tions and trisomy 21 (and thus an extra copy of the APP gene) each
faithfully recapitulate features of AD pathology including in-
creased Ab production and elevated tau phosphorylation
[26,28,29]. The presence of overlapping phenotypes in multiple
patients with the same mutation, as well as mutations in different
genes linked to the same disease, provides increased confidence
that iPSC can be used to reveal disease phenotypes. Importantly,
gamma secretase inhibitors prevented increased Ab production in
these cells, demonstrating the suitability of iPSC-neurons as a
platform for drug screening [26,29].
Further, iPSC have provided evidence for the importance of
correct cellular context in disease models. Spinocerebellar ataxia
type 3 is caused by an expansion of a polyglutamine coding repeat
in the ATXN3 gene. iPSC-neurons generated from SCA3 patients
recapitulate the pathological hallmark of SCA3 patients: accumu-
lation of detergent-insoluble aggregates of full length and cleaved
Ataxin 3 [25]. This phenotype was specific to neurons, and
furthermore was dependent on the presence of functional ion
channels, demonstrating the ability of iPSC to uncover disease
mechanisms by allowing the study of mutations in the context of
functional human neurons.
The use of iPSC as disease models is reviewed comprehensively
by Cherry et al [30]. There is now compelling evidence of the
power of patient-derived iPSC to model disease pathology, offer
insight into disease mechanisms and act as a platform for drug
screening. However, it has also become apparent that there is
extensive intra- and inter- patient variability (23, 25), and it is
necessary to use both multiple iPSC lines per patient and multiple
patients per gene in order to reliably assign disease phenotypes.
Although the sporadic forms of AD, PD and ALS are common,
the familial forms caused by defined mutations are relatively rare,
and for many research groups interested in these and other rarer
neurological diseases, the limiting factor in the use of iPSC is
access to patient fibroblasts with the disease-causing mutations of
interest. For HD, where all affected individuals have the same type
of mutation, an expanded CAG trinucleotide repeat, it is desirable
to have access to subjects with a range of expansion size, which is
the primary determinant of the rate of pathogenesis. Furthermore,
recent reports have demonstrated the necessity of using multiple
patient lines with mutations in the same gene, in order to ensure
that observed cellular phenotypes are caused by the genetic lesion
of interest and not patient variability [25,26]. With this in mind,
our goal was to generate a resource of fibroblast cell lines with
mutations that are linked to neurological disease. There are
currently 67 mutation-defined fibroblast lines available to request
from the Coriell repository, and more lines currently undergoing
expansion and quality control. These include cell lines with
multiple different mutations in each specific gene as well as cell
lines from multiple patients carrying the same mutation. Further
lines will be collected and deposited as patients are identified in
A Fibroblast Resource for Disease Research
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Table 1. Fibroblast lines generated in this study.
Clinical Gene Inheritance Mutation Number of lines Status Reference
AD PSEN1 D Y115H 1 Submitted [33]
PSEN1 D M146I 1 Available [34]
PSEN1 D E184D 1 Available [35]
PSEN1 D P264L 1 Available [33]
PSEN1 D R278I 1 Submitted [36]
PD SNCA D Triplication 1 Available [37]
LRRK2 D R1441G 2 Available
LRRK2 D R1441C 2 Available [38,39]
LRRK2 D G2019S 20 19 Available [40–42]
LRRK2 D G2019S homozygote 2 [43]
GBA N370S 4 Available [42,44]
GBA L444P 1 [42,44]
PARK2 R R42P, DExon 3 1 Available [45,46]
PARK2 R D255, DExon 3–4 1 Available [45,46]
PARK2 R DExon 3–4 homozygote 1 Submitted
PARK2 R R275W/R275Q 1 Available [47]
PINK1 R Q456X homozygote 1
PINK1 R D525N/W577R 1
HD HTT D CAG repeat, range 38–57 17 Available
ALS SOD1 D A4V 2
SOD1 D C38G 1
SOD1 D L38V 1 Available
SOD1 D E49K 1
SOD1 D G86R 1
SOD1 D A89V 1
SOD1 R D90A 2 Available
SOD1 D D91A 1 Available
SOD1 D E100G 1 Available
SOD1 D N138K 1
SOD1 D I112T 1
SOD1 D I113T 6 2 Available
SOD1 D L144P 2 1 Available
SOD1 D V148G 1 Available
TARDBP D G298S 1 Available
FTDP-17T MAPT D P301L 2 Available [48]
MAPT D V337M 2 Available [49]
MAPT D N279K 1 Available [50,51]
MAPT D Exon 10+16 5 [52]
MAPT D R406W 2 [53]
FTDP-17U GRN D A9D 1 Available [54]
GRN D R493X 1 [55]
FTD VCP D R155H 1 [56]
Perry Syndrome DCTN1 D T72P 1 Available [57,58]
Dystonia THAP1 D I149T 1 [59,60]
Ataxia CACNA1A D R1346X 1
Disease, gene, mutation and mode of inheritance for fibroblast cell lines. The current status of each line (available, submitted but not yet in catalogue) is indicated.
Where the status is left blank, this indicates fibroblast lines have been generated but are awaiting submission to the NINDS repository. All variants are heterozygous
unless otherwise stated. References indicate where families have been described in the literature. D = autosomal dominant, R = autosomal recessive.
doi:10.1371/journal.pone.0043099.t001
A Fibroblast Resource for Disease Research
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clinics for participation in this study. This represents a significant
resource that will encourage the use of patient-derived cell models
in research by the wider scientific community.
Methods
Patient consent and protection of privacy
In this study, for all biopsy samples taken, the subsequent
generation and distribution of human cell lines, and the deposition
of these cell lines in the NINDS repository were agreed by the
patients using consent forms and patient information sheets that
were reviewed and approved by local research ethics committees.
Each sample is pseudoanonymised in a systematic way upon
leaving the clinic. There are minor physical risks associated with
the skin punch biopsy procedure, including the possibility of
infection. These risks, as well as the relative benefits of
participating in this study are also discussed with participants
during the informed consent process. It is stressed that immediate
benefits to the patients themselves are unlikely, but use of these cell
lines for in vitro research will lead to an overall enhancement of our
understanding of the basic disease mechanisms. In the future, this
could result in the development of novel therapeutics. For some
lines, consent specifically includes commercial use of the cells and
pathogenic pathway discovery (but not for direct cellular
therapeutics). However, cell lines will not be sold for profit and
patients are informed that they will not benefit financially from
any products or tests that arise from the use of these cells. We have
found that patients were typically enthusiastic about participation
in this study, and we are confident that we will expand our
collection of patient-derived cell lines in the future.
Fibroblast generation
Fibroblasts were generated from a 3–6 mm skin punch biopsy
taken under local anaesthetic following informed consent. Biopsies
were dissected into ,1 mm pieces and cultured in 5 cm2 petri
dishes in DMEM, 10% FBS, 1% L-Glutamine until fibroblasts
were seen to grow out from the explants. When fibroblasts reached
confluency, they were detached from culture dishes using TrypleE
(Invitrogen) and transferred to larger culture vessels for further
expansion. Cells are frozen at the lowest passage possible while still
obtaining an adequate number of total cells for distribution
(typically 2–4 passages or approximately 26107 total cells; cells are
distributed at 56105 cells per ampoule). The passage number of
the cells on distribution depends on demand for a particular cell
line, however 40–60 ampoules of cells are generally derived per
biopsy, whilst keeping the passage number between 2–4. Cells will
be distributed at the lowest available passage, which is indicated
for each sample listed in the Repository online catalogue.
Quality control of fibroblast cultures
Fibroblast cultures are tested for Mycoplasma contamination
prior to frozen storage, and after recovery from liquid nitrogen
prior to distribution. The gender of cell lines is verified by PCR
with a Y chromosome-specific primer pair. Replicate cultures or
matched cultures of differing cell types from the same individual
are analyzed by PCR using microsatellite and Y chromosome-
specific primer pairs to assure cell culture identity.
Immunocytochemistry
Fibroblasts were fixed in 4% paraformaldehyde for 30 min at
room temperature then blocked and permeabilised in blocking
buffer (10% FBS, 0.1% Triton X-100 in phosphate buffered saline)
for 30 min at room temperature. Cells were incubated with rabbit
polyclonal anti-FSP1 (1:100, Abcam) and mouse monoclonal anti-
human fibroblasts clone TE-7 (1:100, Millipore) diluted in
blocking buffer overnight at 4uC. Cells were then incubated with
Alexa Fluor 488 and 568 antibodies (1:500) for 1 h at room
temperature and nuclei were stained using DAPI. Images were
acquired using a Zeiss LSM 710 confocal microscope.
Western blotting
Cells were washed in PBS and then lysed on ice for 30 minutes
in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% v/v Tween-
20, 0.2% NP40, 10%v/v Glycerol) containing Complete protease
inhibitor cocktail (Roche). Lysates were centrifuged for 10 min at
11,000 g(av), 4uC and protein concentrations were estimated using
the BioRad DC Protein Assay Kit. Equal amounts of protein were
electrophoresed on NuPAGE 4–12% Bis-Tris Gels (Invitrogen)
and transferred onto nitrocellulose membranes (Whatman).
Membranes were probed with primary antibodies to FSP-1 (rabbit
polyclonal, 1:500, Abcam) and b-actin (mouse monoclonal,
1:5000, Sigma Aldrich) overnight at 4uC. Membranes were then
incubated with appropriate secondary antibodies (AlexaFluor 680
anti-mouse IgG, Invitrogen and IRDye 800 anti-rabbit IgG,
Rockland Immunochemicals, both 1:5000) for 1 h at RT before
visualisation using an Odyssey Infrared imaging system (LI-COR
Biosciences).
Population doubling levels
Population doubling level (PDL) is a measurement of the total
number of times the cells within the population have doubled since
their primary isolation. PDLs were calculated using the following
equation:
PDL~
3:32 log total viable cells atharvest=total viable cells at seedð Þð Þ
The total viable cells at seed was determined at the first seeding
following proliferation of cells from the skin explant, or from the
frozen ampoule for fibroblast cultures generated outside of Coriell.
The total number of viable cells at harvest was determined
immediately prior to cryopreservation.
Figure 1. Fibroblast cultures express the mesenchymal markers
FSP1 and TE7. Cells generated from skin punch biopsies were verified
as fibroblasts by morphological assessment (A) and positive staining
with antibodies to fibroblast-specific protein 1 (FSP1) and fibroblast-
specific clone TE7 (B, 636). All fibroblasts examined (n = 6) demon-
strated positive staining with both antibodies.
doi:10.1371/journal.pone.0043099.g001
A Fibroblast Resource for Disease Research
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Results
Collection of fibroblast cell lines
We have generated a collection of fibroblast cell lines from
patients with mutations that are linked to neurodegenerative
disorders, including AD, PD, ALS, FTD, HD, dystonias and
ataxias. Also included in the collection are idiopathic sporadic
Parkinson’s disease fibroblast lines and normal control fibroblast
lines, including family members of mutation carriers. These have
been deposited in the National Institute for Neurological Disorders
and Stroke (NINDS) Repository at the Coriell Institute for
Medical Research (Camden, NJ) and the lines carrying known
mutations are detailed in Table 1. Access to these cell lines is open
to the scientific community and they are available to all
researchers for use in basic research. This collection will be
continually expanded and will be a valuable resource for research
into basic disease mechanisms of neurological disorders. An up to
date list of lines available upon request from the NINDS
Repository can be found at: http://ccr.coriell.org/sections/
collections/NINDS/FibroSubcollList.aspx?SsId = 10&PgId= 681.
Fibroblast cell lines are deposited along with a clinical data
elements (CDE) form that outlines the clinical background of the
patient from whom the cells are derived. This protects the identity
of the patient (see below) while providing the end-user with
confidence in the clinical diagnosis. CDE’s for PD, ALS, and HD
have been developed with input from researchers in the field. For
AD and other dementia cell lines, there is currently no CDE;
however, information (e.g., sex, year of birth, and MMSE score at
the time of biopsy) is included.
Figure 2. Fibroblast morphology and marker expression remain consistent during prolonged culture. Fibroblast lines were
immunostained with antibodies FSP1 and TE7 at multiple consecutive passages (A). Passage numbers are indicated above the panels. Morphology,
FSP1 and TE7 staining did not change during five consecutive subculturings (n = 6, representative images from line NM34737, carrying the PSEN1
M146I mutation are shown). FSP1 levels were also detected by western blotting of fibroblast cell lysates (B). FSP1 was detected as a single band at
12 kDa in all fibroblast lines examined (top panel, n = 6). b-actin was used as a loading control (bottom panel). No variation in FSP1 levels was
observed between passages or between cell lines.
doi:10.1371/journal.pone.0043099.g002
A Fibroblast Resource for Disease Research
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Fibroblast cultures are available upon request to all research
laboratories, including those in industry. Users wishing to request
cells are asked to complete a statement of research intent and
complete a NINDS Repository Materials Transfer Agreement
(MTA).
Skin explant-derived cell lines express the fibroblast-
specific proteins FSP1 and TE7
For all fibroblast lines generated, the identity and purity of each
line was confirmed by assessment of characteristic spindle-shaped
morphology (Fig. 1A) [31]. We also immunostained a subset of
lines (n = 6) for fibroblast-specific protein 1 (FSP1) and TE-7,
which detects an epitope specifically expressed by cells that are
mesenchymal in origin. All fibroblast lines examined showed
strong cytoplasmic staining of both FSP1 and TE7, confirming
that cells cultures established from skin explants are indeed
fibroblasts (Fig. 1B). Next, we examined the expression of FSP1
and TE-7 over multiple passages, to ensure that the properties of
the fibroblast lines were not altered by increased time in culture.
We found that the morphology of fibroblast lines remained
unchanged throughout five consecutive passages. Likewise, FSP1
and TE-7 were highly expressed in all cells and did not show
altered levels, or altered distribution, during continuous culture
(Fig. 2A). FSP1 levels were also examined by western blot
(Figure 2B). In fibroblast cell lysates, FSP1 was detected as a single
band at the expected molecular weight of 12 kDa (Fig. 2B). FSP1
was expressed at high levels in all cell lines examined (n= 6) and
the levels of FSP1 were not different between cell lines, or between
different passages.
Population doubling levels
Fibroblasts have a limited proliferative lifespan in culture, and
are able to complete a finite number of cell divisions before
reaching senescence (the Hayflick limit) [61]. As passage number is
a reflection only of the number of times a particular cell line has
been subcultured, and not a reflection of the absolute time in
culture of that particular cell line, the population doubling level
(PDL) of each fibroblast line available in the NINDS catalogue was
determined. PDL is a measure of the total number of times a cell
population has doubled since its initial isolation in vitro. The PDLs
of fibroblast lines in our collection varied from 2.89–7.7 (Table
S1). Fig. 3 shows the range and mean PDLs of the control
fibroblasts, and fibroblast lines from each disease group. A similar
range of PDL variability was seen across all disease groups and the
mean PDLs of fibroblasts were ,5 for each of the categories
represented by the collection. Thus, fibroblast lines requested from
the NINDS repository are comparable in terms of the absolute
time in culture of the cell. Senescence of human diploid fibroblast
cultures does not occur until after 40–50 population doublings
[62]. Therefore, cell cultures within our collection have low
population doubling numbers and can be expanded sufficiently by
the end-users prior to senescence. Furthermore, although the
proliferative capacity of the starting cell population may impact on
reprogramming efficiency, both our control and disease lines
should retain sufficient proliferative capacity to be suitable for
reprogramming to iPSCs.
Discussion
The search for the genetic basis of disease has provided the
impetus for the generation of animal and cell models that
recapitulate key disease features and allow better understanding
of the underlying biological mechanisms leading to cell death. A
major challenge to understanding the basis of neurological
disorders is our ability to model disease causing mutations at
physiological levels, in a relevant cell type. The recent develop-
ment of iPSCs, which can subsequently be differentiated into
neurons and glial cells, is redefining the way we approach in vitro
modelling of neurological disorders. We have developed a
collection of primary fibroblast lines from patients carrying
mutations that are associated with neurological disorders that
can be accessed by all bona fide research groups.
Although others have developed collections of disease-specific
iPSCs [32], we focussed on developing fibroblast cell lines. The
cell lines in our collection express high levels of the fibroblast
markers FSP-1 and TE-7, and are cryopreserved at low population
doubling levels for distribution. However, although fibroblasts are
the most common cell type in cultures established from dermal
outgrowths, these cultures actually represent a heterogeneous cell
population including endothelial cells, pericytes and several types
of stem/progenitor cells [62]. This cellular diversity could
influence the ability of each individual fibroblast line to give rise
to iPSC.
The molecular mechanisms underlying the reprogramming of
fibroblasts to iPSC are poorly understood and there has been
much debate as to whether the process is stochastic (all cells within
a given population have the potential to be reprogrammed) or elite
(only a subset of cells with particular properties can be
reprogrammed). In a recent study, Wakeo and colleagues
determined that iPSC were exclusively generated from a sub-
population of cells positive for both the stem cell marker SSEA3
and the mesencyhmal marker CD105 [63]. These cells, termed
muse cells (multilineage-differentiating stress enduring cells),
express the pluripotency markers Oct3/4, Nanog and Sox2 and
represent approximately 2% of cells present in fibroblast cultures.
This work provides support for the elite model of reprogram-
ming and suggests the efficiency of reprogramming from each of
the fibroblast cultures within this collection may depend on the
proportion of Muse cells present, which was not examined in this
study. However, even in a pure Muse cell population the efficiency
of reprogramming remains low (0.03%), and it therefore seems
likely that there is some stochastic influence on reprogramming.
This notion is supported by multiple reports describing the
addition of extra reprogramming factors and small molecules that
Figure 3. Population doubling levels of fibroblast cell lines.
Population doubling levels were calculated for each of the cell lines
available in the NINDS repository at the time of cryopreservation.
Individual points of the graph correspond to the PDL of individual
fibroblast lines, the horizontal line represents the mean PDL for each
disease category. PDLs ranged between 2–8 with a mean PDL of ,5 for
both control and disease cell lines. A full list of PDLs for individual cell
lines in provided in Table S1.
doi:10.1371/journal.pone.0043099.g003
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increase the efficiency of reprogramming (reviewed in [64]). Thus,
the elite vs stochastic debate remains open, but it is important for
research groups requesting cells described in this manuscript to be
aware of the implications of fibroblast culture diversity. By making
fibroblast lines available, the end-users retain the flexibility to
reprogram by their method of choice.
This collection contains cell lines with mutations in a wide range
of genes as well as multiple different mutations in each gene. In
many cases, cell lines from several patients with the same mutation
are available which will control for patient variability and allow
robust phenotypes to be defined. The rarity of familial forms of
neurological diseases means this represents a valuable resource
which we anticipate will be widely used by the scientific
community, advancing the use of patient cells for in vitro disease
modelling.
Supporting Information
Table S1 Population doubling levels for fibroblast lines
in the NINDS repository. NINDS reference number, disease,
mutation and population doubling level for each cell line currently
available from the NINDS repository.
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